S. Le Pogam | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where S. Le Pogam is active.

Explore More

Publication

Featured researches published by S. Le Pogam.

Journal of Hepatology | 2012

1177 RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNa-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS

Gregory T. Everson; Curtis Cooper; Christophe Hézode; Mitchell L. Shiffman; Eric M. Yoshida; T. Beltran-Jaramillo; Peter Ferenci; Stefan Zeuzem; Michael J. Brunda; Nancy S. Shulman; Mercidita T. Navarro; Athina Voulgari; Isabel Najera; S. Le Pogam; Ellen S. Yetzer

with some preliminary data indicating that at least one of the mutations in NS4B confers partial Legalon-SIL resistance in cell culture. Conclusion: Mutations selected during Legalon-SIL treatment in vivo and in cell culture primarily map to viral membrane attachment regions in NS3 and NS4B, arguing for a primary mode of action targeting RNA replication independent of inhibition of the viral polymerase. Further phenotypic analysis of the mutants will help to elucidate the mechanism of action of Silibinin.

Journal of Hepatology | 2012

1192 HIGH SUSTAINED VIROLOGICAL RESPONSE RATES WITH RESPONSE-GUIDED DANOPREVIR PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE, HCV GENOTYPE 1 PATIENTS: ATLAS STUDY FINAL RESULTS

P. Marcellin; Curtis Cooper; Luis A. Balart; Dominique Larrey; Terry D. Box; Eric M. Yoshida; Eric Lawitz; Peter Buggisch; Peter Ferenci; Martin Weltman; E. Labriola-Tompkins; S. Le Pogam; Isabel Najera; D.N. Thomas; Gregory Hooper; Nancy S. Shulman; Y. Zhang; Mercidita T. Navarro; C.Y. Lim; Michael J. Brunda; Ellen S. Yetzer; Norah A. Terrault

1191 LOW RATE OF ON-TREATMENT RESISTANCE TO DANOPREVIR BOOSTED BY RITONAVIR (DNVR) COMBINED WITH PEG-IFNa-2A/RIBAVIRIN: 12 WEEK INTERIM ANALYSIS FROM DAUPHINE STUDY S. Le Pogam, M. Navarro, L. Bu, A. Voulgari, M. Illnicka, J.M. Yan, K. Klumpp, I. Najera. Virology Discovery, Hoffmann-La Roche, Nutley, NJ, Biostatistics, Genentech, South San Francisco, CA, USA; Biostatistics, Roche Pharma Development in Asia Pacific, Shanghai, China; Clinical Development, Roche Products Ltd, Welwyn, UK; Discovery Technologies, Hoffmann-La Roche, Nutley, NJ, USA E-mail: [email protected]

Journal of Hepatology | 2009

958 NO EVIDENCE OF R7128 DRUG RESISTANCE AFTER UP TO 4 WEEKS TREATMENT OF GT 1, 2 AND 3 HEPATITIS C VIRUS INFECTED INDIVIDUALS

S. Le Pogam; A. Seshaadri; Alan Kosaka; Steven Hu; A. Beard; S. Julian; C. Nick; Isabel Najera

Journal of Hepatology | 2008

21 LOW LEVEL OF RESISTANCE, LOW VIRAL FITNESS AND ABSENCE OF RESISTANCE MUTATIONS IN BASELINE QUASISPECIES MAY CONTRIBUTE TO HIGH BARRIER TO R1626 RESISTANCE IN VIVO

S. Le Pogam; A. Seshaadri; Hyunsoon Kang; Alan Kosaka; Steven Hu; Julian Symons; Klaus Klumpp; Nick Cammack; Isabel Najera

Journal of Hepatology | 2011

62 ACTIVITY OF DANOPREVIR PLUS LOW-DOSE RITONAVIR (DNV/R) IN COMBINATION WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN (PEGIFNa-2A/RBV) IN PREVIOUS NULL RESPONDERS

Regine Rouzier; Dominique Larrey; Edward Gane; A. Wiercinska-Drapalo; L. Chang; Y. Zhang; B. Gujral; S. Le Pogam; Isabel Najera; Patrick F. Smith; Nancy S. Shulman; Jonathan Q. Tran

Journal of Hepatology | 2008

851 ANTIVIRAL POTENCY OF R1479, ACTIVE COMPOUND DERIVED IN VIVO FROM PRODRUG R1626, DEMONSTRATED ACROSS HCV GENOTYPES 1-6 IN NS5B RECOMBINANT ENZYMES AND HCV REPLICONS

Vincent Leveque; S. Le Pogam; Hyunsoon Kang; Gloria Ao-Ieong; Alan Kosaka; A. Seshaadri; Julian Symons; Nick Cammack; Klaus Klumpp; Isabel Najera

Journal of Hepatology | 2007

[602] INHIBITION OF HCV REPLICATION BY PSI-6130: CHARACTERIZATION OF ACTIVITY IN THE HCV REPLICON SYSTEM

Wen-Rong Jiang; Samir Ali; S. Le Pogam; C. Daniel; Sophie Chiu; T. Kretz; Isabel Najera; P. Furman; Nick Cammack; Julian Symons

Journal of Hepatology | 2012

1191 LOW RATE OF ON-TREATMENT RESISTANCE TO DANOPREVIR BOOSTED BY RITONAVIR (DNVR) COMBINED WITH PEG-IFNa-2A/RIBAVIRIN: 12 WEEK INTERIM ANALYSIS FROM DAUPHINE STUDY

S. Le Pogam; Mercidita T. Navarro; L. Bu; Athina Voulgari; M. Illnicka; Jun-Mei Yan; Klaus Klumpp; Isabel Najera

Journal of Hepatology | 2011

1227 LOW PREVALENCE OF DANOPREVIR RESISTANCE IDENTIFIED IN GT1B HCV PATIENTS WITH PRIOR NULL RESPONSE TREATED WITH DANOPREVIR PLUS LOW-DOSE RITONAVIR PLUS PEGIFNα-2A(40KD)/RBV FOR 12 WEEKS

S. Le Pogam; Jun-Mei Yan; M. Chhabra; M. Ilnicka; Y. Ji; Y. Zhang; Nancy S. Shulman; Klaus Klumpp; Isabel Najera

Antiviral Research | 2007

Sub Micromolar Inhibitors of HCV Generated from Inactive Nucleosides by Application of ProTide Technology

Christopher McGuigan; Plinio Perrone; G Luoni; Mary Rose Kelleher; Felice Daverio; A Angell; Sinead Mulready; Costantino Congiatu; Sonal Rajyaguru; Joseph A. Martin; Vincent Leveque; S. Le Pogam; Isabel Najera; Klaus Klumpp; David Bernard Smith

Explore More